ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Chronic Obstructive Pulmonary Disease
Obstructive Lung Diseases
Allergic Rhinitis
Nasal Polyps
Respiration Disorders
Respiratory Tract Diseases

Asthma trials near Montréal, QC, CAN:

Locations recently updated

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations ...

Enrolling
Asthma
Drug: Placebo
Drug: Benralizumab

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 83 other locations

compared with placebo in participants with moderate-to-severe asthma.Study details include:* The study duration for each participant will be...

Begins enrollment in 1 month
Asthma
Drug: Placebo to AZD4604
Drug: AZD4604

Phase 2

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 20 other locations

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled co...

Enrolling
Asthma
Biological: Tezepelumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 99 other locations

Locations recently updated

and formoterol fumarate metered dose inhaler relative to budesonide metered dose inhaler in adults and adolescents with inadequately controlled asthma...

Enrolling
Asthma
Drug: BFF MDI 160/9.6 μg BID (320/19.2μg/day)
Drug: BD MDI 160 μg BID (320 μg/day)

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 139 other locations

of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all partici...

Enrolling
Asthma
Biological: Placebo
Biological: Mepolizumab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Greenfield Park, Quebec, Canada and 429 other locations

the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma...

Enrolling
Asthma
Drug: BD MDI 320 μg
Drug: Open-label Symbicort TBH 320/9 μg

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 181 other locations

decline in adult patients with uncontrolled moderate to severe asthma.The estimated duration is 4±1 weeks of screening and run-in period, fo...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

Phase 4

Sanofi
Sanofi

Montreal, Quebec, Canada and 214 other locations

compared to omalizumab* To evaluate the effect of dupilumab on asthma control at Week 24 compared to omalizumab* To evaluate the safety of ...

Active, not recruiting
Asthma
Chronic Rhinosinusitis With Nasal Polyps
Drug: Omalizumab
Drug: Placebo

Phase 4

Sanofi
Sanofi

Montreal, Quebec, Canada and 94 other locations

This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with CRSwNP.

Active, not recruiting
Nasal Polyps
Biological: Depemokimab (GSK3511294)
Drug: Placebo

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Montreal, Quebec, Canada and 109 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems